Switch maintenance with darolutamide shows promise in previously treated mCRPC

Delegates walking 3

This picture was taken during a previous ESMO congress

Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study

Results from a proof-of-concept trial, presented as a Late-Breaking Abstract today at the ESMO Congress 2021, suggest that switch maintenance with darolutamide may be a valuable new concept in the treatment of metastatic castration-resistant prostate cancer (mCRPC) (LBA26).

The double-blind phase II SAKK 08/16 study involved 92 randomised patients with mCRPC, prior therapy with novel hormonal agents (NHA; abiraterone and/or enzalutamide) and non-progressive disease on taxane-based chemotherapy (docetaxel ≥300 mg/m2 or cabazitaxel ≥80 mg/m2). Patients received darolutamide 600 mg or placebo twice daily 2–8 weeks after the end of the chemotherapy. Median follow-up was 18 months.

The primary endpoint of radiographic progression-free survival (rPFS) at 12 weeks was significantly improved with darolutamide (64.7%) compared with placebo (52.2%; p=0.127, below significance level of 0.15). There was significant prolongation of median rPFS with darolutamide than placebo (5.5 months versus 4.5 months; hazard ratio [HR] 0.54; 95% confidence interval [CI] 0.32–0.91; p=0.017) and median EFS (5.4 months versus 2.9 months; HR 0.46; 95% CI 0.29–0.73; p<0.001). Prostate-specific antigen 50% response occurred in 22% of patients receiving darolutamide but only 4% of those receiving placebo. No significant difference in overall survival was observed between darolutamide and placebo (24 months versus 21.3 months; HR 0.62; 95% CI 0.3–1.26; p=0.181).

LBA26_ESMO 2021

Figure. Radiographic PFS with darolutamide versus placebo in patients with mCRPC (Abstract LBA26, ESMO 2021)

Regarding tolerability, treatment-related adverse events were mild and similar with darolutamide and placebo: grade 1, 26% versus 22%; grade 2, 13% versus 15%; grade 3, both 2%. Grade 1/2 fatigue was less common with darolutamide than placebo (11% versus 20%). 

Cathomas R. Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16). ESMO Congress 2021, LBA26 

Mini oral session – Genitourinary tumours, prostate 19.9.2021, h. 17.35 –17.40, Channel 2

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.